Kenneth J. Hillan
Kenneth J. Hillan is on the board of Sangamo Therapeutics, Inc., Zymeworks BC, Inc. and Zymeworks, Inc. and Chief Therapeutics Officer at 23andMe Holding Co.
In the past Dr. Hillan was CEO, Director & President-R&D Division at Achaogen, Inc., Senior VP & Head-Clinical Development at Genentech, Inc., Member of Roche Group and Head-Therapeutics at 23andMe, Inc.
Dr. Hillan received a doctorate from the University of Glasgow School of Medicine.
Transactions
Date
Transaction
Value
| 11/20/2022 | 4,628 | Derivative/Non-derivative trans. at $2.99 per share. | 13,838 |
| 08/24/2022 | 8,753 | Disposition at $3.64 per share. | 31,861 |
| 08/20/2022 | 4,628 | Derivative/Non-derivative trans. at $3.33 per share. | 15,412 |
| 06/01/2022 | 4,627 | Derivative/Non-derivative trans. at $2.82 per share. | 13,049 |
| 02/09/2022 | 214,091 | Award at $0 per share. | 0 |
